<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01750086</url>
  </required_header>
  <id_info>
    <org_study_id>2012P001956</org_study_id>
    <nct_id>NCT01750086</nct_id>
  </id_info>
  <brief_title>Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption</brief_title>
  <official_title>Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the relative antiresorptive properties of 2 osteoporosis
      medications when combined with teriparatide.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Turnover Marker (Blood Sample)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The primary outcome was the between-group difference in the teriparatide-induced change in serum c-telopeptide from baseline to week 8.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Denosumab 60mg subcutaneous injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alendronate 70mg weekly x 8 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide 40-mcg subcutaneous injection</intervention_name>
    <arm_group_label>Denosumab 60mg subcutaneous injection</arm_group_label>
    <arm_group_label>Alendronate 70mg weekly x 8 weeks</arm_group_label>
    <other_name>Forteo速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab Injection</intervention_name>
    <description>One-time Denosumab injection</description>
    <arm_group_label>Denosumab 60mg subcutaneous injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate Oral Tablet</intervention_name>
    <description>weekly alendronate for 8 weeks</description>
    <arm_group_label>Alendronate 70mg weekly x 8 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Must satisfy A and B and C below:

        A. Women aged 45+

        B. Postmenopausal

        C. Osteoporotic with high risk of fracture

        Exclusion Criteria:

          -  History of significant hepatic, renal, cardiovascular, malignant disease, or
             conditions with impaired immune system

          -  Current alcohol or substance abuse

          -  Major psychiatric disorders

          -  Abnormal calcium level, elevated PTH, vitamin D deficiency, or anemia

          -  Known congenital or acquired bone disease other than osteoporosis

          -  Current use or past use in the past 12 months of oral bisphosphonates

          -  Current use or use in the past 3 months of estrogens, selective estrogen receptor
             modulators, or calcitonin

          -  Use of oral or parenteral glucocorticoids for more than 14 days in the past 6 months

          -  Any current or previous use of strontium or intravenous bisphosphonates

          -  Sensitivity to cell-derived drug products or teriparatide

          -  Extensive dental work involving dental extraction or dental implant within the past 2
             months or in the upcoming 2 months

          -  Inability to sit upright for 30 minutes

          -  Esophageal abnormalities
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cosman F, Eriksen EF, Recknor C, Miller PD, Gua単abens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res. 2011 Mar;26(3):503-11. doi: 10.1002/jbmr.238.</citation>
    <PMID>20814967</PMID>
  </reference>
  <reference>
    <citation>Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003 Sep 25;349(13):1216-26. Epub 2003 Sep 20.</citation>
    <PMID>14500805</PMID>
  </reference>
  <reference>
    <citation>Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med. 2005 Aug 11;353(6):566-75.</citation>
    <PMID>16093465</PMID>
  </reference>
  <reference>
    <citation>Kostenuik PJ, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, Lacey DL, Dunstan CR. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology. 2001 Oct;142(10):4295-304.</citation>
    <PMID>11564687</PMID>
  </reference>
  <reference>
    <citation>Finkelstein JS, Wyland JJ, Lee H, Neer RM. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010 Apr;95(4):1838-45. doi: 10.1210/jc.2009-1703. Epub 2010 Feb 17.</citation>
    <PMID>20164296</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2012</study_first_submitted>
  <study_first_submitted_qc>December 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2012</study_first_posted>
  <results_first_submitted>November 30, 2016</results_first_submitted>
  <results_first_submitted_qc>November 30, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 26, 2017</results_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Benjamin Leder, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>postmenopausal</keyword>
  <keyword>denosumab</keyword>
  <keyword>teriparatide</keyword>
  <keyword>alendronate</keyword>
  <keyword>Forteo速</keyword>
  <keyword>Prolia速</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
    <mesh_term>Bone Resorption</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Teriparatide</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Denosumab 60mg Subcutaneous Injection</title>
          <description>Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.
Teriparatide 40-mcg subcutaneous injection</description>
        </group>
        <group group_id="P2">
          <title>Alendronate 70mg Weekly x 8 Weeks</title>
          <description>Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.
Teriparatide 40-mcg subcutaneous injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Denosumab 60mg Subcutaneous Injection</title>
          <description>Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.
Teriparatide 40-mcg subcutaneous injection</description>
        </group>
        <group group_id="B2">
          <title>Alendronate 70mg Weekly x 8 Weeks</title>
          <description>Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.
Teriparatide 40-mcg subcutaneous injection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" spread="7"/>
                    <measurement group_id="B2" value="66" spread="8"/>
                    <measurement group_id="B3" value="66" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bone Turnover Marker (Blood Sample)</title>
        <description>The primary outcome was the between-group difference in the teriparatide-induced change in serum c-telopeptide from baseline to week 8.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 60mg Subcutaneous Injection</title>
            <description>Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.
Teriparatide 40-mcg subcutaneous injection</description>
          </group>
          <group group_id="O2">
            <title>Alendronate 70mg Weekly x 8 Weeks</title>
            <description>Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.
Teriparatide 40-mcg subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Turnover Marker (Blood Sample)</title>
          <description>The primary outcome was the between-group difference in the teriparatide-induced change in serum c-telopeptide from baseline to week 8.</description>
          <units>percentage of change in CTX</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7" spread="11"/>
                    <measurement group_id="O2" value="43" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Denosumab 60mg Subcutaneous Injection</title>
          <description>Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.
Teriparatide 40-mcg subcutaneous injection</description>
        </group>
        <group group_id="E2">
          <title>Alendronate 70mg Weekly x 8 Weeks</title>
          <description>Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.
Teriparatide 40-mcg subcutaneous injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <description>One subject experienced lightheadedness 3 hours after the first teriparatide injection</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>One subject experienced lightheadedness and syncope 3 hours after the first teriparatide injection</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Joy Tsai</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-6723</phone>
      <email>jntsai@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

